arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2406.00511physics.med-ph
收藏

使用JulianA为头颈癌患者进行质子治疗自动治疗计划的临床效用

Clinical utility of automatic treatment planning for proton therapy of head-and-neck cancer patients using JulianA

Renato Bellotti, Alexey Cherchik, Jonas Willmann, A. Lomax, Damien Charles Weber, Jan Hrbacek

AI总结:

本研究评估自动计划系统JulianA在17例头颈癌质子治疗中的临床效用,发现其生成的计划可接受度与剂量适形度优于人工计划,可作为临床质控工具与研究平台。

摘要:

背景:自动治疗计划为研究和临床环境带来了诸多益处。对于临床而言,自动计划有望缩短计划时间,实现更具可比性的治疗计划,从而减少计划者间的差异。此外,它可以通过提供最低计划质量标准来协助临床医生进行质量保证。最后,自动计划是患者选择的重要组成部分,这对于质子治疗本身的发展至关重要。方法:一项回顾性计划研究,使用了在我们机构接受治疗的17名头颈癌患者队列。将剂量师制定的临床接受计划(d-plans)与自动生成的JulianA计划(j-plans)进行比较。两种方法使用相同的射束安排。计划由两名专家审查者在不知晓各计划生成方式的情况下进行分析。他们评估了计划质量并表达了偏好。结果:所有j-plans均被认为相当或明显可接受,其可接受度高于d-plans。在14例(82.4%)中j-plan被认为更优,1例(5.9%)质量相当,仅2例(11.8%)劣于d-plan。审查者得出结论,在j-plans至少与d-plans一样好的15例(88.2%)中,JulianA实现了更适形的剂量分布。结论:结果表明JulianA已准备好在我们机构用作临床质量保证工具和研究平台。尽管这些结果令人鼓舞,但仍需进一步研究以进一步减少点数,并在优化算法中引入鲁棒性考量,以便将其日常用于患者治疗。

英文摘要:

Background: Automatic treatment planning promises many benefits for both research and clinical environments. For clinics, autoplanning promises to reduce planning time and achieve more comparable treatment plans and thereby reduce inter-planner variability. Further, it can assist clinicians in quality assurance by providing a minimum plan quality standard. Finally, autoplanning is an essential part of patient selection, which is crucial for the advancement of proton therapy itself. Methods: A retrospective planning study using a cohort of 17 head-and-neck cancer patients treated at our institute. The clinically accepted plans created by dosimetrists (d-plans) were compared to automatically generated JulianA plans (j-plans). Both methods used the same beam arrangement. The plans were analysed by two expert reviewers without knowing how each plan was created. They assessed the plan quality and stated a preference. Results: All of the j-plans were deemed rather or clearly acceptable, resulting in a higher acceptability than the d-plans. The j-plan was considered superior in 14 (82.4%) cases, of equal quality for 1 (5.9%) and inferior to the d-plan for only 2 (11.8%) of the cases. The reviewers concluded that JulianA achieves more conformal dose distributions for the 15 (88.2%) cases where the j-plans were at least as good as the d-plans. Conclusions: The results show that the JulianA is ready to be used as a clinical quality assurance tool and research platform at our institute. While these results are encouraging, further research is needed to reduce the number of spots further and introduce robustness considerations into the optimisation algorithm in order to employ it on a daily basis for patient treatment.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑